Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 2, 2015
Pharmacy Choice - News - Generic Drugs - September 2, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 59     Next >>     Go To Page:

9/2/15 - Allergan Announces FDA Approval of Updated Label for TEFLARO (ceftaroline fosamil)
Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application to update the label for TEFLARO for the treatment of adult patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. "The new clinical data in the TEFLARO label will
9/2/15 - Analysis Shows Amgen's Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag
Specifically, VOI Consulting found that the actual cost for Amgen's Blincyto in the news recently following a decision by the Centers for Medicare& Medicaid Services to subsidize its use with hospitalized Medicare patients is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. According to To
9/2/15 - Australia,India : STRIDES ARCOLAB buys INR 1,910-crore Aspen s Generic Business In Australia [TendersInfo (India)]
Strides Arcolab has announced the completion of the Rs 1,910- crore purchase of Aspen Pharmacare s generic pharmaceutical business and related assets in Australia. The transaction has now been completed of closing conditions and statutory and regulatory approvals, Strides Arcolab said. Strides Arcolab has inked deals to buy a generic pharma busines
9/2/15 - Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally
The European market follows closely with Germany, Italy and the United Kingdom offering the highest growth potential for both generic and branded drugs. New analysis from Frost& Sullivan, A Competitive Analysis of the Global Acute Coronary Syndrome Therapeutics Market, finds that the market earned revenues of $13.95 billion in 2014 and estimates th
9/2/15 - Elite Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Elite Pharmaceuticals, Inc. a specialty pharmaceutical company which manufactures and sells niche generic products and is developing a pipeline of pharmacological abuse deterrent opioids, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman& Renshaw 17 th Annual Healthcare Conference o
9/2/15 - FTSE 100 loses early gains as oil price slides again
There were a few bright spots in the falling FTSE 100. Hikma was 99 p higher at 23.24 after a positive note from Barclays in the wake of the pharmaceutical group s $2.65 bn purchase of the generics drug division of US business Boehringer Ingleheim. At a point when the market was fixated on colchicine, and unfounded claims that growth was over-
9/2/15 - FTSE 100 loses early gains on China fears as oil price slides again
There were a few bright spots in the falling FTSE 100. Hikma was 99 p higher at 23.24 after a positive note from Barclays in the wake of the pharmaceutical group s $2.65 bn purchase of the generics drug division of US business Boehringer Ingleheim. At a point when the market was fixated on colchicine, and unfounded claims that growth was over-
9/2/15 - Mapi Pharma Enters into Co-Development Agreement for Risperdal LAI
Deal Type: Partnership Deal Sub Type: Co-development Deal Country: Israel Deal Status: Completed Deal Value: 0.0000 USD. Mapi Pharma Ltd., a developer of generic drugs, has entered into an agreement with a pharmaceutical company, to jointly develop, manufacture and commercialization of Risperidone LAI, a generic depot formulation of Risperdal Const
9/2/15 - Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceeding against Third Copaxone 40 mg/mL Dosing Patent on All Claims
HERTFORDSHIRE, England and PITTSBURGH, Sept. 2, 2015/ PRNewswire/ Mylan N.V. today announced that the U.S. In August 2014, the U.S. Food and Drug Administration accepted Mylan's abbreviated new drug application filing for a three times per week Glatiramer Acetate Injection 40 mg/mL, the generic version of Copaxone 40 mg/mL Mylan believes it is on
9/2/15 - Par Pharmaceutical Begins Shipment of Generic AndroGel 1%
Par Pharmaceutical today announced that it has begun shipping testosterone gel 1%. The U.S. Food and Drug Administration previously approved Par's Abbreviated New Drug Application for the product. According to IMS Health data, annual U.S. sales of testosterone gel 1% packets are approximately $206 million.
9/2/15 - Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines
WASHINGTON, Sept. 2, 2015/ PRNewswire-USNewswire/ On Tuesday, September 1, 2015, six groups representing a broad spectrum of physicians who prescribe biologics Alliance for Patient Access, American Association of Clinical Endocrinologists, American College of Rheumatology, Biologics Prescribers Collaborative, Coalition of State Rheumatology...
9/2/15 - Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ? (ceftazidime-avibactam) In Complicated Urinary Tract Infections
Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ? as a treatment for adult hospitalized patients with complicated urinary tract infections, including pyelonephritis. Ceftazidime-avibactam was approved by the US Food and Drug Administration as AVYCAZ in.
9/2/15 - Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
AstraZeneca today announced positive topline results from RECAPTURE 1 and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI, as a treatment for adult hospitalised patients with complicated Urinary Tract Infections, including pyelonephritis. In the US, where AstraZeneca's partner Allergan holds the commercialisation...
9/2/15 - Studies from University of Turin Reveal New Findings on Biologics (Biosimilar vs biological agents in rheumatology: When are biosimilar agents...
According to news reporting from Turin, Italy, by NewsRx journalists, research stated, "With the introduction of biological agents, over the last two decades treatment prospects in many medical fields including Rheumatology have experienced an exciting revolution. The news correspondents obtained a quote from the research from the University of Tur
9/2/15 - TWi Pharmaceuticals Updates on Resignation of President & CEO Tina Guilder [Professional Services Close - Up]
TWi Pharmaceuticals reported that its President and CEO Tina Guilder will resign from her current roles. Dr. Chen will also lead the Company in its continued execution and strengthening of its research and development, business strategies and further promotion of its business expansion in the United States and international generics markets.
9/1/15 - Allergan Successfully Completes Naurex Acquisition
Allergan acquired Naurex for a $560 million upfront payment net of cash acquired, $460 million of which is payable upon the closing of the acquisition and $100 million of which is payable by January of 2016, as well as potential R&D success-based and sales-threshold milestone payments. This is an area of medicine that requires new ways to tackle so
9/1/15 - Can-Fite Releases Financial Results for 6 Months Ended June 30 [Health & Beauty Close - Up]
Can-Fite BioPharma reported financial results for the six months ended June 30, and updates on its drug development programs. Patent and Trademark Office granted Can-Fite a patent covering the manufacturing process for CF101 in the U.S. and the World Health Organization accepted "piclidenoson" as the proposed generic name for CF101, both important
9/1/15 - FASTER GLOBAL FDA APPROVALS TO HELP INDIAN GENERIC DRUG MAKERS
There are 4,000 pending applications for generic drugs at the United States Food and Drug Administration, of which a fourth is estimated to have been filed by Indian generic drug makers. US FDA is expected to clear at least 470 generic products in 2015 up from 409 approvals in 2014. The number may even cross 500 if the UD FDA does not seek addition
9/1/15 - Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 - a G-CSF & GM-CSF Competitor Analysis
Dublin- Research and Markets has announced the addition of the "Filgrastim& Pegfilgrastim Biosimilars& Biosuperiors 2015- a G-CSF& GM-CSF Competitor Analysis" report to their offering. With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets.
9/1/15 - Perrigo buys scar management co ScarAway [Globes, Tel Aviv, Israel]
Sept. 01 Pharmaceutical manufacturer Perrigo Company is still conducting business as usual in attempts to ward off a takeover by generic rival Mylan N.V.. Three days after completing the $200 million acquisition of GSK's OTC portfolio, Perrigo has announced today that it has acquired ScarAway, a leading US OTC scar management brand, from Enaltus,
9/1/15 - Research and Markets Adds Report: China Insulin Aspart Market Report 2010-2019 [Manufacturing Close - Up]
Developed by Novo Nordisk, insulin aspart is an important drug for the treatment of diabetes. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. Currently, the market is dominated by Novo Nordisk and Novo Nordisk, the former enjoying a larger market share of 100 percent wi
9/1/15 - Research and Markets: Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 - a G-CSF & GM-CSF Competitor Analysis
Research and Markets has announced the addition of the "Filgrastim& Pegfilgrastim Biosimilars& Biosuperiors 2015- a G-CSF& GM-CSF Competitor Analysis" report to their offering. With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar fil
8/31/15 - Allergan Successfully Completes Naurex Acquisition
DUBLIN, Aug. 31, 2015/ PRNewswire/ Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, including depression. Allergan acquired
8/31/15 - Lannett Receives FDA Approval, Launches Generic Antidepressant Drug ABILIFY
By a News Reporter-Staff News Editor at Pharma Business Week Lannett Company, Inc. announced that its Silarx Pharmaceuticals, Inc. subsidiary has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Aripiprazole Oral Solution 1 mg/mL, the generic version of the antidepressant drug ABILIFY.
8/31/15 - Mylan Confirms First-to-File Patent Challenge Relating to Zytiga
By a News Reporter-Staff News Editor at Pharma Business Week Mylan N.V. confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research& Development, LLC in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Abirat
Articles(s): 1 - 25 of 59     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415